Key result
Left atrial decompression devices show potential for HFpEF but success hinges on proper patient selection.
Why the study?
HFpEF still has limited approved treatment options and poor uptake, but several innovative devices such as left atrial decompression devices are being evaluated in clinical trials.
Does device therapy, such as left atrial decompression devices, provide therapeutic benefit for patients with heart failure with preserved ejection fraction (HFpEF)?
Does device therapy, such as left atrial decompression devices, provide therapeutic benefit for patients with heart failure with preserved ejection fraction (HFpEF)?
Device therapies, particularly left atrial decompression devices, represent an innovative and emerging treatment strategy for patients with HFpEF who currently have limited therapeutic options.
Device therapy for HFpEF remains investigational; leaves open the need to identify responsive patient subsets.
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of epidemic proportions associated with elevation of left sided heart pressures despite a left ventricular ejection fraction (LVEF) of > 50%. 1 Patients with HFpEF have signs and symptoms of heart failure (HF) similar to patients with HF with reduced ejection fraction (HFrEF) and account for slightly greater than half of all patients with HF. 2 Prognosis for both HFpEF and HFrEF are similar and are markedly worse than those of the general population. 3 Unlike HFrEF, which has had several evidenced based therapies for decades, HFpEF still has limited approved treatment options, and uptake for many patients is poor. However, there are several innovative devices that are being evaluated in clinical trials for the treatment of HFpEF, most notably left atrial decompression devices. A key driver for the success of these therapies will be defining the appropriate patient population to study within the broader HFpEF population.
No takes yet. Share an insight, caveat, or question.
Lilly et al. (2025) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Device therapy (left atrial decompression devices) was evaluated. Innovative devices, notably left atrial decompression devices, are being evaluated for HFpEF, with success depending on defining the appropriate patient population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: